Particularly for high morbidity surgeries in older or compromised patients, cancer surgeons need to be sure they have removed as much cancer as possible while the patient is still on the table, since callback surgeries are hard on these patients and come at significant costs to health care systems. Surgeons currently rely on pathology to verify surgical margins; however, in this case, many surgical specimens are too bulky to be imaged with our ADEPT Imager. In response, we have built a prototype of a cancer topography imaging system that can image the depth of cancer cells if they are fluorescently labeled (fluorescence is being translated to clinical cancer imaging at an incredible rate with more than a dozen clinical trials ongoing in North America at present). We are currently working with Max Witjes, MD at the University of Groningen, who is leading the world’s first clinical trial (NCT03134846) that can use fluorescence to guide surgery (see select references [5-8]);. Funding: NIH R21 CA1215561